Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation

Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (P<0.05). In addition, 5-FU injection caused pronounced tissue injury accompanied by increased neutrophil accumulation, tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) tissue levels, and positive immunostaining for TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS). Interestingly, amifostine prevented the inflammatory reaction and consequently improved macroscopic and microscopic damage (P<0.05 vs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.

Saved in:
Bibliographic Details
Main Authors: Barbosa,S.C.M., Pereira,V.B.M., Wong,D.V.T., Santana,A.P.M., Lucetti,L.T., Carvalho,L.L., Barbosa,C.R.N., Callado,R.B., Silva,C.A.A., Lopes,C.D.H., Brito,G.A.C., Alencar,N.M.N., Lima-Júnior,R.C.P.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2019
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000300601
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2019000300601
record_format ojs
spelling oai:scielo:S0100-879X20190003006012019-03-18Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivationBarbosa,S.C.M.Pereira,V.B.M.Wong,D.V.T.Santana,A.P.M.Lucetti,L.T.Carvalho,L.L.Barbosa,C.R.N.Callado,R.B.Silva,C.A.A.Lopes,C.D.H.Brito,G.A.C.Alencar,N.M.N.Lima-Júnior,R.C.P. Cancer chemotherapy toxicity Oral mucositis 5-Fluorouracil Amifostine Cytokines Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (P<0.05). In addition, 5-FU injection caused pronounced tissue injury accompanied by increased neutrophil accumulation, tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) tissue levels, and positive immunostaining for TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS). Interestingly, amifostine prevented the inflammatory reaction and consequently improved macroscopic and microscopic damage (P<0.05 vs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.52 n.3 20192019-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000300601en10.1590/1414-431x20188251
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Barbosa,S.C.M.
Pereira,V.B.M.
Wong,D.V.T.
Santana,A.P.M.
Lucetti,L.T.
Carvalho,L.L.
Barbosa,C.R.N.
Callado,R.B.
Silva,C.A.A.
Lopes,C.D.H.
Brito,G.A.C.
Alencar,N.M.N.
Lima-Júnior,R.C.P.
spellingShingle Barbosa,S.C.M.
Pereira,V.B.M.
Wong,D.V.T.
Santana,A.P.M.
Lucetti,L.T.
Carvalho,L.L.
Barbosa,C.R.N.
Callado,R.B.
Silva,C.A.A.
Lopes,C.D.H.
Brito,G.A.C.
Alencar,N.M.N.
Lima-Júnior,R.C.P.
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
author_facet Barbosa,S.C.M.
Pereira,V.B.M.
Wong,D.V.T.
Santana,A.P.M.
Lucetti,L.T.
Carvalho,L.L.
Barbosa,C.R.N.
Callado,R.B.
Silva,C.A.A.
Lopes,C.D.H.
Brito,G.A.C.
Alencar,N.M.N.
Lima-Júnior,R.C.P.
author_sort Barbosa,S.C.M.
title Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_short Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_full Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_fullStr Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_full_unstemmed Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_sort amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
description Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (P<0.05). In addition, 5-FU injection caused pronounced tissue injury accompanied by increased neutrophil accumulation, tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) tissue levels, and positive immunostaining for TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS). Interestingly, amifostine prevented the inflammatory reaction and consequently improved macroscopic and microscopic damage (P<0.05 vs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.
publisher Associação Brasileira de Divulgação Científica
publishDate 2019
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000300601
work_keys_str_mv AT barbosascm amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT pereiravbm amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT wongdvt amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT santanaapm amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT lucettilt amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT carvalholl amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT barbosacrn amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT calladorb amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT silvacaa amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT lopescdh amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT britogac amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT alencarnmn amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
AT limajuniorrcp amifostinereducesinflammationandprotectsagainst5fluorouracilinducedoralmucositisandhyposalivation
_version_ 1756391582984044544